222 related articles for article (PubMed ID: 32577400)
1. Cefiderocol for treatment of an empyema due to extensively drug-resistant
Kufel WD; Steele JM; Riddell SW; Jones Z; Shakeraneh P; Endy TP
IDCases; 2020; 21():e00863. PubMed ID: 32577400
[TBL] [Abstract][Full Text] [Related]
2. Cefiderocol Antimicrobial Susceptibility Testing Considerations: the Achilles' Heel of the Trojan Horse?
Simner PJ; Patel R
J Clin Microbiol; 2020 Dec; 59(1):. PubMed ID: 32727829
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
Karlowsky JA; Hackel MA; Tsuji M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Apr; 53(4):456-466. PubMed ID: 30471402
[TBL] [Abstract][Full Text] [Related]
4.
Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630181
[TBL] [Abstract][Full Text] [Related]
5.
Nakamura R; Ito-Horiyama T; Takemura M; Toba S; Matsumoto S; Ikehara T; Tsuji M; Sato T; Yamano Y
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262762
[TBL] [Abstract][Full Text] [Related]
6. Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth.
Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
Diagn Microbiol Infect Dis; 2019 Aug; 94(4):321-325. PubMed ID: 31029489
[TBL] [Abstract][Full Text] [Related]
7. Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design.
Huband MD; Ito A; Tsuji M; Sader HS; Fedler KA; Flamm RK
Diagn Microbiol Infect Dis; 2017 Jun; 88(2):198-200. PubMed ID: 28410852
[TBL] [Abstract][Full Text] [Related]
8. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
9. Comparison of disk diffusion, MIC test strip and broth microdilution methods for cefiderocol susceptibility testing on carbapenem-resistant enterobacterales.
Bonnin RA; Emeraud C; Jousset AB; Naas T; Dortet L
Clin Microbiol Infect; 2022 Aug; 28(8):1156.e1-1156.e5. PubMed ID: 35533970
[TBL] [Abstract][Full Text] [Related]
10. Assessment of cefiderocol disk diffusion versus broth microdilution results when tested against
Liu Y; Ding L; Han R; Zeng L; Li J; Guo Y; Hu F
Microbiol Spectr; 2023 Dec; 11(6):e0535522. PubMed ID: 37855593
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria.
Wang Y; Li Y; Zhao J; Guan J; Ni W; Gao Z
Ann Transl Med; 2022 Mar; 10(5):261. PubMed ID: 35402576
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Variability in Interpretation of Disk Diffusion Testing for Cefiderocol Using Different Brands of Mueller-Hinton Agar.
Potter RF; Wallace MA; Muenks CE; Alvarado K; Yarbrough ML; Burnham CD
J Appl Lab Med; 2023 May; 8(3):523-534. PubMed ID: 36738243
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study.
Bleibtreu A; Dortet L; Bonnin RA; Wyplosz B; Sacleux SC; Mihaila L; Dupont H; Junot H; Bunel V; Grall N; Razazi K; Duran C; Tattevin P; Dinh A; The Cefiderocol French Study Group OBO
Microorganisms; 2021 Jan; 9(2):. PubMed ID: 33573148
[TBL] [Abstract][Full Text] [Related]
15. Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing.
Matuschek E; Longshaw C; Takemura M; Yamano Y; Kahlmeter G
J Antimicrob Chemother; 2022 May; 77(6):1662-1669. PubMed ID: 35289853
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model.
Ghazi IM; Monogue ML; Tsuji M; Nicolau DP
Int J Antimicrob Agents; 2018 Feb; 51(2):206-212. PubMed ID: 29111435
[TBL] [Abstract][Full Text] [Related]
17. Compassionate Use of Cefiderocol in the Treatment of an Intraabdominal Infection Due to Multidrug-Resistant Pseudomonas aeruginosa: A Case Report.
Stevens RW; Clancy M
Pharmacotherapy; 2019 Nov; 39(11):1113-1118. PubMed ID: 31550054
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against
Carcione D; Siracusa C; Sulejmani A; Migliavacca R; Mercato A; Piazza A; Principe L; Clementi N; Mancini N; Leoni V; Intra J
Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827247
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model.
Monogue ML; Tsuji M; Yamano Y; Echols R; Nicolau DP
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848004
[TBL] [Abstract][Full Text] [Related]
20. Cefiderocol is an effective topical monotherapy for experimental extensively-drug resistant
Romanowski EG; Mumper SM; Shanks HQ; Yates KA; Mandell JB; Zegans ME; Shanks RMQ
bioRxiv; 2023 Sep; ():. PubMed ID: 37693441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
